These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26229068)

  • 21. [Mechanisms of action, pharmacology and interactions of dolutegravir].
    Ribera E; Podzamczer D
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():2-8. PubMed ID: 25858605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Tolerability of Integrase Inhibitors in Antiretroviral-Naive Patients.
    D'Abbraccio M; Busto A; De Marco M; Figoni M; Maddaloni A; Abrescia N
    AIDS Rev; 2015; 17(3):171-85. PubMed ID: 26450805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
    Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Mos1 transposase in vivo assay to screen new HIV-1 integrase inhibitors.
    Cancian M; Loreto ELS
    Genetica; 2018 Apr; 146(2):243-247. PubMed ID: 29352755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
    Quercia R; Roberts J; Martin-Carpenter L; Zala C
    Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
    Wu B; Tang J; Wilson DJ; Huber AD; Casey MC; Ji J; Kankanala J; Xie J; Sarafianos SG; Wang Z
    J Med Chem; 2016 Jul; 59(13):6136-48. PubMed ID: 27283261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dolutegravir as a trigger for DRESS syndrome?
    Martin C; Payen MC; De Wit S
    Int J STD AIDS; 2018 Sep; 29(10):1036-1038. PubMed ID: 29621952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A safety evaluation of raltegravir for the treatment of HIV.
    de Miguel R; Montejano R; Stella-Ascariz N; Arribas JR
    Expert Opin Drug Saf; 2018 Feb; 17(2):217-223. PubMed ID: 29199485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability of HIV integrase inhibitors.
    Lee FJ; Carr A
    Curr Opin HIV AIDS; 2012 Sep; 7(5):422-8. PubMed ID: 22886031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
    van Lunzen J; Maggiolo F; Arribas JR; Rakhmanova A; Yeni P; Young B; Rockstroh JK; Almond S; Song I; Brothers C; Min S
    Lancet Infect Dis; 2012 Feb; 12(2):111-8. PubMed ID: 22018760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of dolutegravir safety for the treatment of HIV-1.
    Keeshin SW; Feinberg J
    Expert Opin Drug Saf; 2015 Jan; 14(1):141-7. PubMed ID: 25347230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse events of raltegravir and dolutegravir.
    Elzi L; Erb S; Furrer H; Cavassini M; Calmy A; Vernazza P; Günthard H; Bernasconi E; Battegay M;
    AIDS; 2017 Aug; 31(13):1853-1858. PubMed ID: 28692533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Integrase inhibitors - new challenges for the treatment of HIV-1 infections].
    Stock I
    Med Monatsschr Pharm; 2013 Dec; 36(12):448-59; quiz 461-2. PubMed ID: 24450269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.
    Townsend CL; O'Rourke J; Milanzi E; Collins IJ; Judd A; Castro H; Vicari M; Jesson J; Leroy V; Renaud F; Penazzato M
    J Int AIDS Soc; 2022 Nov; 25(11):e25970. PubMed ID: 36377082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
    Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
    Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral therapy: dolutegravir sets SAIL(ING).
    Boyd MA; Donovan B
    Lancet; 2013 Aug; 382(9893):664-6. PubMed ID: 23830358
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug safety profile of integrase strand transfer inhibitors.
    Gutierrez Mdel M; Mateo MG; Vidal F; Domingo P
    Expert Opin Drug Saf; 2014 Apr; 13(4):431-45. PubMed ID: 24597519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination.
    Nishana M; Nilavar NM; Kumari R; Pandey M; Raghavan SC
    Cell Death Dis; 2017 Jun; 8(6):e2852. PubMed ID: 28569776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.
    Sibiude J; Le Chenadec J; Mandelbrot L; Dollfus C; Matheron S; Lelong N; Avettand-Fenoel V; Brossard M; Frange P; Reliquet V; Warszawski J; Tubiana R;
    AIDS; 2021 Feb; 35(2):219-226. PubMed ID: 33048878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.